Who are SHEN26 capsule's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BNT162b5 Bivalent (WT/OMI BA.2), BNT162b2 (2025/2026 formulation), Combination BNT162b2 and BNT162b2 OMI, batch 1 of Ad5-nCoV, BNT162b6 Bivalent (Original/OMI BA.4/BA.5), BNT162b4 5 mcg.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/shen26-capsule.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

SHEN26 capsule — Competitive Intelligence Brief

SHEN26 capsule (SHEN26 capsule) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Infectious Disease.

phase 3 vaccine SARS-CoV-2 spike protein Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

SHEN26 capsule (SHEN26 capsule) — Shenzhen Kexing Pharmaceutical Co., Ltd.. SHEN26 capsule is a vaccine that targets the SARS-CoV-2 spike protein.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
SHEN26 capsule TARGET	SHEN26 capsule	Shenzhen Kexing Pharmaceutical Co., Ltd.	phase 3	vaccine	SARS-CoV-2 spike protein
BNT162b5 Bivalent (WT/OMI BA.2)	bnt162b5-bivalent-wt-omi-ba-2	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
BNT162b2 (2025/2026 formulation)	bnt162b2-2025-2026-formulation	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
Combination BNT162b2 and BNT162b2 OMI	combination-bnt162b2-and-bnt162b2-omi	Pfizer	marketed	mRNA vaccine	SARS-CoV-2 spike protein
batch 1 of Ad5-nCoV	batch 1 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
BNT162b6 Bivalent (Original/OMI BA.4/BA.5)	bnt162b6-bivalent-original-omi-ba-4-ba-5	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein
BNT162b4 5 mcg	bnt162b4-5-mcg	Pfizer	marketed	vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SHEN26 capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/shen26-capsule. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab